natgillin/translations-raw huggingface dataset:
In certain embodiments, the stable pre-fusion RSV F polypeptides according to the invention comprise a truncated F1 domain and a F2 domain, and a linking sequence comprising from 1 to 10 amino acid residues, linking said truncated F1 domain to said F2 domain, wherein the polypeptides further comprise a mutation of the amino acid residue N or T on position 67 and/or a mutation of amino acid residue S on position 215. 
Prefuzijski RSV F polipeptid prema zahtjevu 1 ili 2, naznačen time što sadrži okrnjenu F1 domenu i F2 domenu, i spojnu sekvencu koja sadrži od 1 do 10 aminokiselinskih ostataka, koji povezuju navedenu F1 domenu na navedenu F2 domenu.
Use according to claim 35, wherein inflammatory conditions and immune disorders are selected from the group consisting of asthma, adult respiratory distress syndrome, chronic obstructive pulmonary disease, inflammatory bowel conditions, Crohn's disease, bronchitis, and cystic fibrosis. 
Upotreba u skladu s patentnim zahtjevom 11, naznačena time što se upalna stanja i imunosne poremećaje bira iz skupine koju čine astma, sindrom dišnog distresa kod odraslih, kronična opstruktivna plućna bolest, upalna stanja crijeva, Crohnova bolest, bronhitis i cistična fibroza.
The composition according to Claim 5, which contains the anthranilamide compound; at least one dispersant selected from the group consisting of a C8-12 polyoxyethylene alkyl aryl ether, a polyoxyethylene tristyrylphenyl ether, a C8-12 alkylbenzene sulfonate and a C8-18 polyoxyethylene alkyl ether phosphoric acid ester; and at least one hydrophilic organic solvent selected from the group consisting of N,N-dimethylacetamide, dimethylsulfoxide, Y-butyrolactone, N-methyl-2-pyrrolidone and cyclohexanone. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time, da sadržava antranilamidni spoj; najmanje jedno sredstvo za disperziranje odabrano iz skupine koju čine C8-12 polioksietilen alkil aril eter, polioksietilen tristirilfenil eter, C8-12 alkilbenzensulfonat i C8-18 polioksietilen alkil eter ester fosforne kiseline; i najmanje jedno hidrofilno organsko otapalo odabrano iz skupine koju čine N,N- dimetilacetamid, dimetilsulfoksid, g-butirolakton, N-metil-2-pirolidon i cikloheksanon.
In yet another embodiment, an aforementioned method is provided wherein the conjugating the water soluble polymer to the oxidized carbohydrate moiety of the therapeutic protein is stopped by the addition of a quenching agent selected from the group consisting of L-cysteine, methionine, glutathione, glycerol, sodium meta bisulfite (Na2S2O5), tryptophane, tyrosine, histidine or derivatives thereof, kresol, imidazol, and combinations thereof; wherein the quenching agent is added in an amount to result in a final concentration between about 1 mM and about 100 mM quenching agent, under conditions comprising a time period between about 5 minutes and about 120 minutes; a temperature between about 2°C and about 37°C; in the presence or absence of light; and with or without stirring. 
Postupak prema zahtjevu 2, pri čemu se konjugiranje polimera topljivog u vodi na oksidirani dio karbohidrata terapeutskog proteina zaustavlja dodavanjem agensa za gašenje odabranog od skupine koja se sastoji od L-cisteina, metionina, glutationa, glicerola, natrij meta bisulfita (Na2S205), triptofana, tirozina, histidina ili njegovih derivata, krezola, imidazola, i njihovih kombinacija; pri čemu je agens za gašenje dodan u količini koja rezultira krajnjom koncentracijom između oko 1 mM i oko 100 mM agensa za gašenje, pod uvjetima koji sadrže vremenski period između oko 5 minuta i oko 120 minuta; temperaturu između oko 2?C 1 oko 37 *C; u prisutnosti 1li odsutnosti svjetla; i s ili bez miješanja.
The method according to Claim 19, wherein the antigen-presenting cell comprises an expression vector according to Claim 9. 
Metoda iz Zahtjeva 13, gdje se stanica koja prikazuje antigen sastoji od vektora ekspresije prema Zahtjevu 6.
and R13, which are the same or different, each represents hydrogen, C1_4 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 haloalkyl, C1-3 alkoxy C1-4 alkyl, C6-10 aryl, 5- to 10-membered heteroaryl, 3- to 10-membered heterocyclyl, C6-10 aryl C1-4 alkyl, 3- to 10-membered heterocyclyl C1-3 alkyl, 5- to 10-membered heteroaryl C1-3 alkyl, cyano(C1-3 alkyl), C1-3 alkylsulfonyl C1-4 alkyl, 3- to 10-membered cycloaliphatic ring, 5- to 10-membered heteroaryl, or 3- to 10-membered heterocyclyl; or alternatively, R12 and R13, together with a nitrogen atom linked thereto, form 3-to 10-membered heterocyclyl or 5- to 10-membered heteroaryl which is optionally substituted by one or more groups independently selected from group Q; 
i R13, koji su jednaki ili različiti, svaki predstavlja vodik, C1-4 alkil, C2-6-alkenil, C2-6-alkinil, C1-4-haloalkil, C1-3-alkoksi-C1-4-alkil, C6-10-aril, 5- do 10-eročlani heteroaril, 3- do 10-eročlani heterociklil, C6-10-aril-C1-4-alkil, 3- do 10-eročlani heterociklil-C1-3-alkil, 5- do 10-eročlani heteroaril-C1-3-alkil, cijano(C1-3-alkil), C1-3-alkilsulfonil-C1-4-alkil, 3- do 10-eročlani cikloalifatski prsten, 5- do 10-eročlani heteroaril, ili 3- do 10-eročlani heterociklil; ili alternativno, R12 i R13, zajedno s atomom dušika vezanim za njih, formiraju 3-to 10-eročlani heterociklil ili 5- do 10-eročlani heteroaril koji je po izboru supstituiran s jednom ili više skupina nezavisno izabranih iz grupe Q;
A is selected from the group consisting of phenyl, pyridyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, and thiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, lower alkyl and lower cycloalkyl; 
A je izabran iz grupe koju čini fenil, piridil, indolil, tienil, benzotienil, indazolil, benzizoksazolil, benzofuranil, benzotriazolil, furanil, benzotiazolil, tiazolil, svaki izborno supstituiran sa jednom ili dvije grupe nezavisno izabran iz grupe koju čini OH, C,4 alkil i C34 cikloalkil;
Industrial process for the direct temperature induced recrystallization of asbestos and/or mineral fibres containing waste products using a tunnel kiln and recycling 
INDUSTRIJSKI PROCES ZA IZRAVNU TEMPERATUROM INDUCIRANU TRANSFORMACIJU I RECIKLIRANJE OTPADA KOJI SADRŽI AZBEST KORISTEĆI TUNELSKU PEĆ
The process of item 16, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 72 °C and the curing time is preferably in the range of from about 15 minutes to about 2 hours. 
Postupak prema zahtjevu 16, naznačen time da temperaturni profil u toku koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura barem oko 72 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 15 minuta do oko 2 sata.
The use according to claim 3, wherein at least one secondary anti-retroviral or other adjunctive therapeutic agent is selected from the group consisting of: protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, combination drugs, entry and fusion inhibitors, acyclovir, adefovir dipivoxil, aldesleukin, amphotericin b, azithromycin, calcium hydroxylapatite, clarithromycin, doxorubicin, dronabinol, entecavir, epotein alfa, etoposide, fluconazole, ganciclovir, immunoglobulins, interferon alfa-2, isoniazid, ribavirin, rifabutin, rifampin, somatropin, testosterone, trimetrexate, valganciclovir; integrase inhibitors, microbicides, and IL-2. 
Uporaba prema zahtjevu 3, gdje se barem jedno dodatno anti-retrovirusno ili drugo dopunsko terapijsko sredstvo odabire iz skupine koju čine: inhibitori proteaze, nukleozidni inhibitori reverzne transkriptaze, ne-nukleozidni inhibitori reverzne transkriptaze, kombinirani lijekovi, inhibitori ulaza i fuzije, aciklovir, adefovir dipivoksil, aldesleukin, amfotericin b, azitromicin, kalcijev hidroksilapatit, klaritromicin, doksorubicin, dronabinol, entekavir, epotein alfa, etopozid, flukonazol, ganciklovir, imunoglobulini, interferon alfa-2, izoniazid, ribavirin, rifabutin, rifampin, somatropin, testosteron, trimetreksat, valganciklovir; inhibitori integraze, mikrobicidi, i IL-2.
A kit comprising a solid formulation according to any one of claims 1 to 16 and a package leaflet or user instruction including the information that said formulation is to be used for the prevention and/or treatment of congestive heart failure in a mammal, preferably in a dog, cat or rodent, in need of such prevention or treatment. 
Garnitura, naznačena time, da obuhvaća kruti pripravak prema bilo kojem od zahtjeva 1 do 16 1 pakirani listić ili uputstvo za korisnika, koji sadrži informaciju da se kruti pripravak treba upotrebljavati za prevenciju i/ili liječenje kongestivnog srčanog zastoja kod sisavca, poželjno kod psa, mačke ili glodavca, kojima treba takva prevencija ili liječenje.
A crystalline HCl salt form of Compound I-5(b), wherein Compound I-5(b) has the chemical structure: and wherein the crystalline HCl salt form is characterized by XRPD by the following reflections with the d-spacing. Position [°2 Theta] d-spacing [Å] 
Kristalni oblik soli HCl Spoja I-5(b), pri čemu Spoj I-5(b) ima kemijsku strukturu: i pri čemu je kristalni oblik soli HCl naznačen time što ima XRPD sa slijedećim refleksijama s d-razmakom.
A pharmaceutical composition according to claim 1 which is an aqueous solution or a sterilised lyophilized powder, comprising a soluble receptor comprising a fragment of the N-terminal extracellular domain (ECD) of human FZD8 linked to a non-FZD receptor protein sequence wherein the amino acid sequence of the fragment consists of residues 28 to 158 of SEQ ID NO: 7, and a pharmaceutically acceptable carrier, excipient and/or stabilizer. 
Farmaceutski sastav, naznačen time, da obuhvaća topivi FZD8-receptor i farmaceutski prihvatljiv nosač, pomoćno sredstvo i/ili stabilizator, pri čemu se aminokiselinska sekvenca od topivog FZD8-receptora sastoji od ostataka 28 do 158 od SEQ ID NO:7, spojenih na sekvencu ne-FZD-receptora, dok sekvenca ne-FZD-receptora sadrži ljudski Fc.
Ingenol-3-angelate or a salt for use according to claim 3 wherein the virus is selected from HPV 6, 11, 30, 42, 43, 44, 45, 51, 52 and 54. 
Ingenol 3-angelat ili njegova sol za uporabu prema zahtjevu 3, naznačen time da je virus izabran iz HPV 1, 2, 3, Ingenol 3-angelat ili njegova sol za uporabu prema zahtjevu 3, naznačen time da je virus izabran iz HPV 6, 11, 30, 42, 43, 44, 45, 51, 52 and 54.
An AAV vector for use in a method for the treatment of a motor neuron disorder in a subject in need thereof, wherein said vector is administered by peripheral administration of said AAV vector to said subject, and wherein; said AAV vector comprises a human AAV9 capsid; and an AAV genome comprising a gene of interest encoding a therapeutic product, said gene of interest being operably linked to a promoter specific or functional in motor neurons. 
AAV vektor koji sadrži gen od interesa za uporabu u metodi za dostavu navedenog gena od interesa kralježničnoj moždini intraperitonealnim (i.p.), intramuskularnim (i.m.) ili intravenskim (i.v.) injiciranjem, poželjno intravenskim injiciranjem, navedenog AAV vektora subjektu, pri čemu je navedeni AAV vektor: dvolančani samokomplementarni AAV9 vektor, ili pseudotipizirani AAV vektor koji sadrži dvolančani samokomplementarni AAV genom deriviran iz AAV serotipa različitog od AAV9 serotipa i kapsidu deriviranu iz AAV9 kapside.
or a humanized version thereof. 
ili njegova humanizirana verzija.
a peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide comprises an amino acid sequence of SEQ ID NO: 288, in which 1 or 2 amino acids are substituted, wherein said peptide induces a cytotoxic T cell specific to an HLA-A2 positive cell expressing URLC10; 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:376 i 379, u kojima su 1 ili 2 aminokiseline zamijenjene, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4.
The method of claim 1, wherein the paroxetine mesylate is in a crystalline form. 
2. - Paroksetin za upotrebu prema patentnom zahtjevu 1, naznačen time što je paroksetin u kristalnom obliku.
A composition suitable for control of diseases caused by phytopathogens comprising a synergistically effective amount of 
L wo ll. Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od:
This application relates to carbohydrate derivatives of rapamycin, a potent immunosuppressant, with structurally defined carbohydrate moieties attached to the rapamycin structure via a connective moiety. 
Ova se prijava odnosi na ugljikohidratne derivate rapamicina, snažnog imunosupresora, sa strukturno definiranim ugljikohidratnim jedinicama pričvršćenim na strukturu rapamicina poveznom jedinicom.
The process according to claim 1, wherein the cation of the at least one water-soluble salt is sodium. The process according to claim 1, wherein the anion of the at least one water-soluble salt is selected from the group consisting of, dihydrogen phosphate, monohydrogen phosphate, hydrates of oxalate, hydrates of silicate, and any mixture thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da je anion navedene kiseline topive u vodi odabran iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, oksalat, silikat, njihove mješavine i njihove hidrate, poželjnije iz skupine koja sadrži fosfat, dihidrogen fosfat, monohidrogen fosfat, njihove mješavine i njihove hidrate, te najpoželjnije iz skupine koja sadrži dihidrogen fosfat, monohidrogen fosfat, njihove mješavine 1 njihove hidrate.
arene represents a benzene, or a benzene substituted with from 1 to 6 linear or branched C1-C6 alkyl groups, or mixtures thereof; 
aren predstavlja benzen, ili benzen supstituiran s od 1 do 6 linearnih ili razgranatih C1-C6 alkil grupa, ili njihove smjese;
Directly after the gluing, the formed block of wood 12 was pressed for 6 hours in the pressing equipment 67 at a pressure of 0.8 N/mm2. 
Neposredno nakon lijepljenja je formirani blok od drva 12 bio prešan kroz 6 sati u opremi za prešanje 67 pod tlakom od 0.8 N/mm'.
It is further preferred that the insulin is derived from the species corresponding to species from which the cell line or cell type is derived, or that it is human insulin. 
Dalje se preporučuje da inzulin bude podrijetlom od vrste od koje je dobivena i stanična linija ili stanični tip, ili da se radi o humanom inzulinu.
The receiver of claim 12, wherein the L1 block has L1 signaling information for the data slice. 
Uređaj prema zahtjevu 11 ili 12, naznačen time, što LI blok ima LI signalizacijsku informaciju za signaliziranje podatkovnog odsječka.
Thereby, in the context of the present invention, it is indeed possible, however not mandatory to keep the humidity content of the wood permanently on or above the fiber saturation point for the duration of the whole process with the exception of step (iv). In this manner, the processes according to the invention are clearly simplified compared to the prior art, for example compared to the process as disclosed in the US 3,969,558. 
Na taj način u vezi s predmetnim izumom, stvarno je moguće, međutim nije obavezno, držati sadržaj vlage drva stalno na točki zasićenja vlakana ili iznad te točke za vrijeme cijelog postupka s izuzetkom faze (iv), pa su na taj način postupci koji su u skladu s ovim izumom jasno pojednostavljeni u usporedbi sa stanjem tehnike, na primjer, u usporedbi s postupkom koji je opisan u US 3,969,558.
by the use of a reducing agent like borane, alane or lithium aluminium hydride. 
korištenjem reducirajućeg agensa kao boran, alan ili litijev aluminijski hidrid.
The CMV vector for use of any one of claims 1-10, wherein the CMV vector encodes US2 as depicted in SEQ ID NO:1, US3 as depicted in SEQ ID NO:2, and US6 as depicted in SEQ ID NO:3. 
Vektor CMV, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što vektor CMV kodira US2 kao što je opisano u SEQ ID NO:1, US3 kao što je opisano u SEQ ID NO:2, te US6 kao što je opisano u SEQ ID NO:3.
reduction of compound 2*, particularly with diisobutylaluminium hydride (DiBAI-H) to create compound D* (having a second benzyl protection group at the nitrogen atom instead of the phenyl fluorenyl group in compound D); 
(a) redukcija spoja 2 ili spoja 2*, osobito s diizobutilaluminij hidridom kako bi se dobio spoj D odnosno D*; od Ho Dad xD ra
The compound of any one of claims 1-10, wherein Z is imidazo[1,2-a]pyridin-2-yl substituted with up to 2 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyloxy, halogen, alkylsulfonyl and cyano. 
Spoj prema bilo kojem od zahtjeva 1-10, naznačen time da je Z imidazo[1,2-a]piridin-2-il supstituiran s najviše 2 supstituenta nezavisno izabrana iz skupine koju sačinjavaju Ci4 alkil, Cia alkoksi, C3-Cg cikloalkil, C2-Cg cikloalkiloksi, halogen, alkilsulfonil 1 cijano.
In such an embodiment, the recipient is treated with FH upon receipt of said allograft until said allograft functions normally. In an exemplary embodiment, normal function of the allograft is determined by recipient creatinine level and/or negative C4d biopsy testing. 
Pripravak u skladu s patentnim zahtjevom 9, namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se normalnu funkciju navedenog alogenog presatka određuje razinom kreatinina kod primatelja i/ili negativnim biopsijskim testiranjem na C4d.
Also provided are kits comprising multiple doses of pharmaceutical composition according to the present invention. In one variation, the kits further comprise instructions which comprise one or more forms of information selected from the group consisting of indicating a disease state for which the pharmaceutical composition is to be administered, storage information for the pharmaceutical composition, dosing information and instructions regarding how to administer the pharmaceutical composition. 
Komplet koji sadrži: višestruke doze farmaceutske kompozicije prema bilo kojem od patentnih zahtjeva 1-38; i uputstva koja sadrže jedan ili više oblika informacija izabranih iz grupe koju čine indikacija stanja bolesti za koju se primjenjuje farmaceutska kompozicija, informacije o čuvanju za farmaceutsku kompoziciju, informacije o doziranju i uputstva u svezi s tim kako primjenjivati farmaceutsku kompoziciju.
In a variation, the quantity of basic nitrogen in the feed is 60 ppm or more. 
Postupak prema jednom od zahtjeva 1 do 8, naznačen time da je količina bazičnog dušika u šarži 60 ppm ili više.
a support for mounting the winch with respect to a sailboat; 
ležište (206) za montiranje vitla u odnosu na jedrilicu;
Also provided herein are methods for isolating a population of recombinant adeno-associated virus (rAAV) particles from in-process impurities in a feedstream, comprising the steps of: (a) contacting a feedstream containing the rAAV particles with a hydrophobic interaction chromatography (HIC) medium in a high salt buffer, wherein the rAAV particles and the in-process impurities bind the HIC medium; and (b) eluting the rAAV particles bound to the HIC medium with a medium salt buffer. 
Postupak za izoliranje populacije čestica rekombinantnog adeno-povezanog virusa (rAAV) od procesnih nečistoća u dolaznoj struji, naznačen time što sadrži slijedeće korake: a. dovođenje u kontakt dolazne struje koja sadrži čestice rAAV s medijem za hidrofobnu interakcijsku kromatografiju (HIC) u puferu visoke koncentracije soli, pri čemu pufer visoke koncentracije soli sadrži između 0.5M i 2.0M citrata, pri čemu se čestice rAAV i procesne nečistoće vežu na HIC medij; i b. eluiranje čestica rAAV vezanih na HIC medij s puferom srednje koncentracije, pri čemu pufer srednje koncentracije soli sadrži manje od 0.5M citrata.
A drive gear 132 is coupled to and driven for rotation by the second electric motor 50. 
Pogonski zupčanik (132) je spojen na drugi elektromotor (50) koji ga zakreće.
withdrawing and re-circulating at least part of said colloidal suspension from said milling chamber to said agitated chamber. 
- < povlačenje 1 re-cirkulaciju najmanje dijela navedene koloidne suspenzije iz navedene komore za mljevenje (4;
The pharmaceutical composition according to claim 7, which is the platelet production regulating agent. A crystal of ethyl 3-(4-carboxy-2,6-dichlorophenyl)-2-methylacrylate having a diffraction angle 2θ of a main peak of powder X-ray diffraction of 8.1, 16.3, 19.2, 20.0, 24.8, and 39.0 degrees. 
Kristal etil 3-(4-karboksi-2,6-diklorofenil)-2-metilakrilata naznačen time da ima glavni vršak kod difrakcije X- zraka na prahu s kutom difrakcije 20 kod 8.1, 16.3, 19.2, 20.0, 24.8, 1 39.0 stupnjeva, pri čemu su uvjeti mjerenja difrakcije X-zraka kako slijedi: vakuumska cijev CuK a-zraka, napon rendgenske cijevi 40kV, struja rendgenske cijevi 40mA ili SOmA.
wherein: and R2 are as defined above, R3 is H or —COCH3; with the proviso that when Y is selected from the bivalent radicals mentioned under b)-f), the —ONO2 group is bound to —(CH2)n1; 
NHF" gdje ni, iR? jesu kao što su gore definirani, R? je Hili -COCH;, s ograničenjem da kada je Y odabran od dvovalentnih radikala spomenutih pod b)-f), -ONO, skupina je vezana za -(CH2),', 2
The lighting module of claim 1, wherein said microchip is configured to operate the switching device such that 330 mA to 450 mA is delivered to the light emitting diode when said thermistor senses between 80° C. to 100° C. 
Rasvjetni modul iz patentnog zahtjeva 1, naznačen time, da je navedeni mikročip konfiguriran da upravlja preklopnim sklopom tako da se LED diodi isporučuje 330 mA do 450 mA kada navedeni termistor odčita temperaturu u rasponu 80% do 100 "€.
A tablet as defined in claim 1, wherein said tablet-shaped pharmaceutical preparation is formed by direct compression. 
Postupak prema zahtjevu 4, naznačen time da je u koraku b) sastav oblikovan direktnom kompresijom navedenog sastava.
The herbicide composition as claimed in claim 3 where 15-60 parts by weight of foramsulfuron and 2500-30000 parts by weight of pelargonic acid are present per part by weight of iodosulfuron-methyl. 
Herbicidna kombinacija prema zahtjevu 6 naznačena time da je prisutno 15-60 masenih dijelova foramsulfurona 1 2500 - 30000 masenih dijelova pelargonijske kiseline po masenom udjelu jodosulfuron-metila.
The composition of claim 4, which composition is an enteric coated tablet. 
Sastav u skladu s patentnim zahtjevom 4, gdje je sastav enterično obložena tableta.
Use according to claim 17 or an MTP inhibitor for use according to claim 17 wherein the lipid modifying compounds are selected from the group consisting of HMG CoA reductase inhibitors, cholesterol absorption inhibitors, ezetimibe, squalene synthetase inhibitors, fibrates, bile acid sequestrants, statins, probucol and derivatives, niacin, niacin derivatives, PPAR alpha agonists, fibrates, PPAR gamma agonists, thiazolidinediones, and cholesterol ester transfer protein (CETP) inhibitors. 
Uporaba prema patentnom zahtjevu 17 ili inhibitor MTP za upotrebu prema patentnom zahtjevu 17, naznačeni time što su spojevi za modifikaciju lipida izabrani iz grupe koju čine inhibitori HMG CoA reduktaze, inhibitori apsorpcije kolesterola, ezetimib, inhibitori skvalen sintetaze, fibrati, sekvestranti žučne kiseline, statini, probukol 1 derivati, niacin, derivati niacina, agonisti PPAR alfa, fibrati, agonisti PPAR gama, tiazolidindioni i inhibitori proteina za transfer kolesterol estra (CETP).
The anti-CD20 antibody formulation for use according to claim 1 or 2, wherein the anti-CD20 antibody is present in an amount of about 50 mg/ml. 
Formulacija protutijela anti-CD20 za uporabu prema zahtjevu 1, saznačena time, da je ofatumumab prisutan u količini od 20 mg/mL.
The pharmaceutical composition for use method of claim 54, wherein the lung disease is asthma. 
Farmaceutski pripravak za uporabu postupka prema zahtjevu 54, naznačen time da je plućna bolest astma.